Images List Premium Download Classic

Anxiety

Anxiety-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Diagnostic and therapeutic methods and products related to anxiety disorders
Emory University
November 30, 2017 - N°20170343561

The present disclosure provides methods for diagnosing and treating anxiety disorders in female subjects. Diagnosis and treatment of such anxiety disorders are based, in part, on an analysis of pituitary adenylate cyclase-activating polypeptide (pacap) expression levels in tissue collected from female subjects.
Anti-acth antibodies and use thereof
Alder Biopharmaceuticals, Inc.
November 23, 2017 - N°20170334987

The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-acth antibodies and binding fragments thereof conjugated ...
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
Alder Biopharmaceuticals, Inc.
November 02, 2017 - N°20170312308

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e. G., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat ...
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method of enhancing a participant's performance in a sporting activity
University Of Kansas
September 14, 2017 - N°20170259149

According to one aspect of the present invention, a method of improving a participant's ability to move an object toward a desired target through athletic movement is provided. The method comprises establishing a point of focus that is positioned outward from a participant's body. The method further comprises instructing the participant to continuously move the point of focus through one ...
Disease susceptibility
Leiden University
August 24, 2017 - N°20170240967

The invention provides a method of assessing the susceptibility of a subject to, or aiding the diagnosis of, an anxiety disorder or depression, the method comprising determining whether the subject has a haplotype comprising rs3216799, rs6814934, rs7658048, rs2070950 and rs2070951 with respective alleles ‘+ct, ‘c’, ‘t’, ‘c’ and ‘c’. The invention ...
Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
Euthymics Bioscience, Inc.
August 17, 2017 - N°20170233333

The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e. G., depression, anxiety disorders, eating disorders and urinary ...
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel anxiolytic compounds
Domes Pharma
June 29, 2017 - N°20170183347

Which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Merck Patentgesellschaft
June 29, 2017 - N°20170182037

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid ...
Exo-s-mecamylamine formulation and use in treatment
University Of South Florida
June 29, 2017 - N°20170181983

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0. 5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-r-mecamylamine, said ...
Neuroplasticity games for depression
University Of South Florida
May 25, 2017 - N°20170148343

A training program is configured to systematically drive neurological changes to treat depression, mood and anxiety disorders. The training program includes an inference renormalization game that presents three subsets of stimuli and prompts a game participant to selectively respond or withhold responding to one or two of the stimulus subsets.
Compositions and methods for the treatment of neurological diseases
University Of South Florida
May 11, 2017 - N°20170129870

The compositions and compounds of formula i which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder, ...
System and method for enabling a user to overcome social anxiety
Dharma Life Sciences Llc
May 04, 2017 - N°20170124905

A system is provided for enabling a user to overcome social anxiety. The system is configured to enable the user to engage in a first and a second activity in a virtual environment, directed to rewire a first and a second defective wiring, respectively. The first defective wiring results in an individual give priority to threatening information in social environments. ...
Magnesium compositions and uses thereof for neurological disorders
Neurocentria, Inc.
April 27, 2017 - N°20170112875

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another ...
Anxiety Patent Pack
Download + patent application PDFs
Anxiety Patent Applications
Download + Anxiety-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Anxiety-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Indolin-2-one or pyrrolo-pyridin-2-one derivatives
Neurocentria, Inc.
April 13, 2017 - N°20170101409

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory ...
Methods of diagnosing and treating anxiety disorder
The Children's Hospital Of Philadelphia
March 30, 2017 - N°20170087141

Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mglur) network genes and wherein treatment is with nonspecific activators of mglurs such as fasoracetam.
Peptides as oxytocin agonists
Hoffmann-la Roche Inc.
March 23, 2017 - N°20170081369

The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.
Peptides as oxytocin agonists
Hoffmann-la Roche Inc.
March 23, 2017 - N°20170081368

The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.
Heteroaromatic compounds and their use as dopamine d1 ligands
Hoffmann-la Roche Inc.
March 02, 2017 - N°20170057947

And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e. G., schizophrenia (e. G., its cognitive and negative symptoms), cognitive impairment (e. G., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, ...
(2r)-2-propyloctanoic acid for functional brain disease
Ono Pharmaceutical Co., Ltd.
February 23, 2017 - N°20170049737

An agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the functional brain disease includes (2r)-2-propyloctanoic acid or a salt thereof. The agent may be safely administered to patients of, for example, functional brain diseases such as depression, menopausal mood disorder, perimenopausal mood disorder, panic disorder, irritable bowel syndrome, social anxiety disorder, ...
Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium ...
The Johns Hopkins University
February 02, 2017 - N°20170029382

The present invention provides compounds of formula i which are capable of inhibition of the activation of hnav1. 1 or hnav1. 6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods for prevention and treatment of neurological disorders, including, for example, seizures and seizure disorders, including lennox-gastaut syndrome, dravet syndrome, epileptic encephalopathies, autism, familial hemiplegic migraine (fhm), anxiety ...
Methods for the treatment of depression and anxiety
The Arizona Board Of Regents On Behalf Of The University Of Arizona
January 26, 2017 - N°20170020953

Methods of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising ac-nle4-c[asp5-his6-(nme)d-nal(2′)7-arg8-trp9-(nme)lys10]-nh2 (peptide 9), in a pharmaceutically acceptable carrier is administered to the subject. Peptide 9 is a selective mc5r antagonist, ...
Loading